US · Healthcare · Medical Care Facilities
EPS came in at 5.52 against a street estimate of 5.12 — a beat of 7.8%.
Analysts rate Chemed Corp a buy (2 buy, 3 hold, 0 sell out of 5) with an average price target of $571.60.
CONFIDENT VITAS exceeded expectations with 9% admission growth and $8.9M cap cushion added; Roto-Rooter stable but facing persistent Google-driven paid-lead inflation; raised full-year VITAS guidance; adjusted EPS up 41.9% YoY. Q2 2026 Florida dominates VITAS cap cushion; California stabilizing. South Texas Roto-Rooter acquisition expands footprint. Analysts pressed on VITAS growth sustainability (Joel confirmed KPI-driven strategy supports long-term double-digit net income growth), Roto-Rooter margin trajectory (management candid: Google shift to paid leads is 'inexorable,' ancillary services + franchises provide offsets), and de novo cap risk (Kevin noted 101-day LOS and hospital mix buffer near-term concerns). Management confident but realistic on headwinds. 2026-07-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 11.36% |
| AQR Capital Management LLC | 7.44% |
| Vanguard Portfolio Management, LLC | 6.02% |
| Vanguard Capital Management, LLC | 4.62% |
| Acadian Asset Management LLC | 3.47% |
| State Street Corp | 3.40% |
| Geode Capital Management, LLC | 3.17% |
| JPMorgan Chase & Co | 3.09% |
| Document | Date |
|---|---|
| Quarterly report · Q2 2026 CHEMED CORPORATION – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Six-month revenue: $1,330.8 million (up 5.1% vs. $1,265.7 million in first six months 2 | 2026-07-31 |
| Results announced · Q3 2026 CHEMED CORPORATION Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenue: $673.3 million, up 8.8% year-over-year • GAAP diluted EPS: $5.1 | 2026-07-28 |
| Shareholder vote results · Q2 2026 CHEMED CORPORATION (CHE) - FORM 8-K SUMMARY HEADLINE NUMBERS • Annual stockholder meeting held May 18, 2026 • Board of 9 directors elected with vary | 2026-05-19 |
| Quarterly report · Q1 2026 CHEMED CORPORATION Q1 2026 10-Q SUMMARY HEADLINE NUMBERS • Total revenues (Q1 2026): $657.513 million vs. $646.943 million (Q1 2025), up 1.6% • Net | 2026-04-28 |
| Results announced · Q2 2026 CHEMED CORPORATION Q1 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated revenue: $657.5 million, up 1.6% year-over-year • GAAP diluted EPS: $4.8 | 2026-04-23 |
| Material agreement · Q2 2026 CHEMED CORPORATION - FORM 8-K SUMMARY HEADLINE NUMBERS • Renewed senior secured credit facilities totaling $450 million • Five-year revolving credit | 2026-04-13 |
| Proxy statement · Q4 2025 CHEMED CORPORATION PROXY STATEMENT SUMMARY WHAT SHAREHOLDERS ARE VOTING ON • Proposal 1 – Election of Directors: Vote to elect 9 directors to serve | 2026-04-06 |
| Annual report FY2025 CHEMED CORPORATION – 2025 FORM 10-K SUMMARY HEADLINE NUMBERS • Market Capitalization (June 30, 2025): $7,010,301,507 at $486.93 per share • Outstand | 2026-02-27 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | $0.70 / share ex-date Aug 17, 2026 · pay Sep 3, 2026 | 2026-08-17 |
| Dividend | $0.60 / share ex-date May 28, 2026 · pay Jun 16, 2026 | 2026-05-28 |
| Dividend | $0.60 / share ex-date Feb 23, 2026 · pay Mar 13, 2026 | 2026-02-23 |
| Dividend | $0.60 / share ex-date Nov 17, 2025 · pay Dec 5, 2025 | 2025-11-17 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Chemed Corp — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.